Lionco Pharm Grp Co Ltd (603669) — Net Asset Quality Index
Lionco Pharm Grp Co Ltd (603669) has a Net Asset Quality Index of 55.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.12 Billion minus total liabilities of CN¥498.43 Million yields net assets of CN¥623.24 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check 603669 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Lionco Pharm Grp Co Ltd Net Asset Quality Index Over Time (2011–2025)
This chart shows how Lionco Pharm Grp Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the index stands at 55.6%, representing net assets of CN¥623.24 Million against total assets of CN¥1.12 Billion CNY. See working capital to net assets of Lionco Pharm Grp Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Lionco Pharm Grp Co Ltd (2011–2025)
The table below presents the year-by-year Net Asset Quality Index for Lionco Pharm Grp Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Lionco Pharm Grp Co Ltd (603669) total market value.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 56.0% | CN¥620.28 Million | CN¥1.11 Billion | CN¥486.50 Million | ▼ -5.3 pp |
| 2024 | 61.3% | CN¥769.76 Million | CN¥1.26 Billion | CN¥485.57 Million | ▲ +4.0 pp |
| 2023 | 57.3% | CN¥931.04 Million | CN¥1.62 Billion | CN¥693.52 Million | ▼ -3.9 pp |
| 2022 | 61.2% | CN¥1.14 Billion | CN¥1.86 Billion | CN¥720.32 Million | ▲ +3.2 pp |
| 2021 | 58.0% | CN¥1.46 Billion | CN¥2.51 Billion | CN¥1.06 Billion | ▲ +3.5 pp |
| 2020 | 54.5% | CN¥1.48 Billion | CN¥2.72 Billion | CN¥1.24 Billion | ▼ -14.2 pp |
| 2019 | 68.7% | CN¥1.31 Billion | CN¥1.91 Billion | CN¥599.60 Million | ▲ +2.0 pp |
| 2018 | 66.6% | CN¥1.38 Billion | CN¥2.07 Billion | CN¥689.97 Million | ▼ -12.0 pp |
| 2017 | 78.7% | CN¥1.30 Billion | CN¥1.65 Billion | CN¥352.40 Million | ▼ -8.3 pp |
| 2016 | 87.0% | CN¥1.17 Billion | CN¥1.34 Billion | CN¥174.57 Million | ▲ +3.7 pp |
| 2015 | 83.3% | CN¥1.12 Billion | CN¥1.34 Billion | CN¥223.98 Million | ▲ +16.5 pp |
| 2014 | 66.8% | CN¥374.13 Million | CN¥559.83 Million | CN¥185.70 Million | ▲ +6.5 pp |
| 2013 | 60.3% | CN¥351.02 Million | CN¥582.12 Million | CN¥231.09 Million | ▼ -4.4 pp |
| 2012 | 64.7% | CN¥236.22 Million | CN¥364.89 Million | CN¥128.67 Million | ▲ +12.1 pp |
| 2011 | 52.6% | CN¥128.55 Million | CN¥244.38 Million | CN¥115.83 Million | — |